Compare JG & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JG | IXHL |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | China | Australia |
| Employees | N/A | 12 |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 40.1M |
| IPO Year | 2018 | 2024 |
| Metric | JG | IXHL |
|---|---|---|
| Price | $7.00 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.6K | ★ 75.3K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $0.16 |
| 52 Week High | $8.58 | $6.39 |
| Indicator | JG | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 41.26 |
| Support Level | $6.25 | $3.11 |
| Resistance Level | $8.32 | $3.94 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 91.89 | 7.84 |
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates in one segment and generates revenues from SAAS Businesses.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.